Overview
BMRN market data
Price History
BMRN price chart
Valuation & Profitability
- P/E (TTM)
- 42.32 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $1.77 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.23 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $49.26 – $66.28 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $11.4K · P/B 1.88 · P/S 3.51.
Company news
Citigroup Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $76Benzinga · Jul 16, 2026, 8:19 PM
8-K/A filing — BIOMARIN PHARMACEUTICAL INC (BMRN)SEC EDGAR · Jul 13, 2026, 8:06 PM
MioMarin Pharmaceuticals Receives FDA Supplemental New Drug Application Approval For Vosoritide To Treat Pediatric AchondroplasiaBenzinga · Jul 13, 2026, 1:07 PM
RBC Capital Maintains Sector Perform on BioMarin Pharmaceutical, Lowers Price Target to $62Benzinga · Jul 7, 2026, 4:05 PM
BioMarin Pharmaceutical Presented New Data From Phase 2 Three-Year Extension Study Of VOXZOGO In 13 Children With Hypochondroplasia That Demonstrated Sustained Improvements In Annualized Growth Velocity And Height Standard Deviation ScoreBenzinga · Jun 16, 2026, 1:20 PM
8-K filing — BIOMARIN PHARMACEUTICAL INC (BMRN)SEC EDGAR · Jun 4, 2026, 8:24 PM
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics LandscapeGlobenewswire Inc · May 26, 2026, 5:15 PM
BioMarin Reveals Dwarfism Study Data, Stock SoarsBenzinga · May 21, 2026, 7:15 PM
BioMarin Pharmaceutical Announces Phase 3 VOXZOGO Study Data Demonstrating Statistically Significant Change From Baseline In Children With HypochondroplasiaBenzinga · May 20, 2026, 8:30 PM
B of A Securities Maintains Buy on BioMarin Pharmaceutical, Lowers Price Target to $80Benzinga · May 19, 2026, 6:55 PM